Skip to content

Trading statement Q1-2025: A landmark deal for GUBamy

  • Jes Jørgensen

Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal worth USD 2.2 billion in upfront and milestones…

Read more

CEO video statement. Q1 2025.

  • Jes Jørgensen

A Transformative Quater for Gubra  Today, we share our Q1 2025 results - a quarter marked by a transformative milestone:   We’ve entered into an out-licensing agreement with AbbVie for our internally developed anti-obesity asset GUBamy. This landmark deal represents a…

Read more

Gubra Welcomes New Board Members at 2025 AGM

  • Jes Jørgensen

Following Gubra’s Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ahead. As recommended by the Nomination Committee, the following members were re-elected…

Read more

Course of Gubra A/S’ Annual General Meeting 2025

  • Jes Jørgensen

On Thursday, 3 April 2025 at 10:00 am (CEST), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda:1. The board of directors’ report on…

Read more

Successful Transaction Closure of License Agreement

  • Jes Jørgensen

With reference to Gubra's A/S (CPSE: GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, all closing conditions…

Read more

NOTICE TO CONVENE ANNUAL GENERAL MEETING 2025

  • Jes Jørgensen

Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the…

Read more
Back To Top